Blood tests can now detect a growing number of brain problems, from the earliest protein changes of Alzheimer’s disease to nerve damage from multiple sclerosis and even misfolded proteins linked to Parkinson’s. The field has accelerated dramatically in the past decade thanks to ultrasensitive measurement technology that can pick up brain-specific proteins circulating in blood at vanishingly low concentrations. These tests are not yet standard for every neurological condition, and none of them replace brain imaging or spinal fluid analysis in all cases. But for several major diseases, blood-based biomarkers have reached accuracy levels that are reshaping how doctors diagnose, monitor, and even predict brain disorders years before symptoms appear.
How Brain Proteins End Up in Your Blood
The brain is protected by the blood-brain barrier, a tightly sealed lining of cells that keeps most blood-borne substances out of neural tissue and most brain proteins locked inside. For decades, this barrier was the reason neurologists assumed useful brain biomarkers could only be found in cerebrospinal fluid, the liquid that bathes the brain and spinal cord, obtained through a lumbar puncture. But the barrier is not perfectly sealed. Small amounts of proteins released by damaged or dying neurons, inflamed support cells, or even tiny membrane-enclosed packages called extracellular vesicles do cross into the bloodstream. Research on plasma proteins has shown that the barrier’s transport mechanisms shift with aging, allowing more protein traffic between brain and blood over time.1Science Translational Medicine. Plasma proteins have a ticket to ride the blood-brain barrier The concentrations are extremely low compared to cerebrospinal fluid, often 50 to 100 times lower, which is why conventional blood assays could never reliably measure them.2PubMed. Development and multi-center validation of a fully automated digital immunoassay for neurofilament light chain: toward a clinical blood test for neuronal injury
The breakthrough came with a technology called single molecule array, or Simoa, which can detect proteins at sub-femtomolar concentrations, meaning it can find individual molecules in a sea of blood plasma.3PubMed Central. An Update on Blood-Based Markers of Alzheimer’s Disease Using the SiMoA Platform That sensitivity turned previously undetectable traces of brain damage into measurable signals, opening the door to blood tests for conditions that were once diagnosable only through expensive imaging or invasive spinal taps.
Alzheimer’s Disease Has the Strongest Evidence
If there is one brain disorder where blood testing has come closest to clinical reality, it is Alzheimer’s disease. The core pathology of Alzheimer’s involves two abnormal proteins accumulating in the brain: amyloid-beta plaques and tangles of phosphorylated tau. Both of these leave detectable footprints in the blood, and the accuracy of blood tests for them is now remarkably high.
The standout marker is phosphorylated tau 217, or p-tau217. In a multi-cohort study, plasma p-tau217 measured with a commercially developed immunoassay predicted abnormal amyloid on PET brain scans with an area under the curve above 0.92, and predicted abnormal tau with accuracy above 0.93.4PubMed Central. Diagnostic accuracy of the plasma ALZpath pTau217 immunoassay to identify Alzheimer’s disease pathology To put that in plain terms, the blood test agreed with brain scans in the vast majority of cases. A fully automated clinical version of this test using Simoa technology has since been validated across multiple centers, employing a two-cutoff approach that classifies results as positive, negative, or intermediate.5PubMed Central. Analytical and clinical validation of a high accuracy fully automated digital immunoassay for plasma phospho-Tau 217 for clinical use in detecting amyloid pathology
Other blood markers add to the picture. The ratio of amyloid-beta 42 to amyloid-beta 40 in plasma drops in people with amyloid pathology, and another tau variant, p-tau181, also rises. Research has found that combining these core biomarkers with GFAP (a marker of brain support cell activation) and neurofilament light chain (a marker of nerve fiber damage) can improve diagnostic accuracy in clinical assessments.6PubMed Central. Plasma p-tau217, p-tau181 and Aβ42/40 for Alzheimer’s disease diagnosis: ROC accuracy and 18F-florbetapir amyloid PET-CT concordance Studies integrating PET, cerebrospinal fluid, and plasma markers are now exploring how blood tests fit into a layered diagnostic approach, using Bayesian probability models to estimate the likelihood of underlying amyloid pathology when different test results are combined.7npj Dementia. Amyloid probability in Alzheimer disease from plasma, cerebrospinal fluid, and amyloid imaging
Neurofilament Light Chain Detects Nerve Damage Broadly
While the Alzheimer’s markers are disease-specific, neurofilament light chain (NfL) works differently. It is a structural protein found inside nerve fibers, and when those fibers are damaged or destroyed, NfL spills into the surrounding fluid and eventually into the blood. This makes it a general-purpose alarm for neuronal injury rather than a pointer to any single disease.8PubMed Central. Neurofilament Light Chain as a Biomarker, and Correlation with Magnetic Resonance Imaging in Diagnosis of CNS-Related Disorders
That breadth is both a strength and a limitation. Blood NfL levels rise in multiple sclerosis, amyotrophic lateral sclerosis (ALS), frontotemporal dementia, Alzheimer’s disease, and after traumatic brain injury. In animal models of ALS and Alzheimer’s, plasma NfL tracks disease progression closely, while in Parkinson’s disease models the changes are much smaller.9PubMed Central. Neurofilament-Light Chain as Biomarker of Neurodegenerative and Rare Diseases With High Translational Value For conditions like ALS, where NfL levels can forecast the shift from a presymptomatic stage to active disease, the clinical utility is already quite real. For others, an elevated NfL level tells the doctor that something is damaging nerves but not what that something is, so it works best alongside disease-specific markers and imaging.
Parkinson’s Disease and the Promise of Seed Amplification
Parkinson’s disease has been harder to pin down with blood tests than Alzheimer’s, partly because its signature protein, alpha-synuclein, is abundant throughout the body and takes on abnormal “misfolded” shapes that are difficult to distinguish from the normal version at low concentrations. A technique called the seed amplification assay (SAA) gets around this by using a tiny amount of misfolded alpha-synuclein in the blood as a “seed” that recruits normal copies to misfold in a test tube, amplifying the signal until it becomes detectable.
Results from a longitudinal study found that all individuals who went on to develop Parkinson’s showed a positive blood-based alpha-synuclein SAA one to ten years before their clinical diagnosis. Among people with a sleep disorder called isolated REM sleep behavior disorder, which is a known risk factor for Parkinson’s, about 30 percent tested positive. All healthy controls tested negative.10PubMed. Detecting Misfolded α-Synuclein in Blood Years before the Diagnosis of Parkinson’s Disease A test that can flag disease a decade before tremor or stiffness appears could be transformative if effective preventive treatments become available.
Stroke, Brain Tumors, and Autoimmune Brain Diseases
Beyond neurodegenerative diseases, blood biomarkers are being explored for more acute brain problems. In stroke, the critical early question is whether the brain is suffering from a blocked artery (ischemic stroke) or a bleed (hemorrhagic stroke), because the treatments are opposite. Among blood samples collected within six hours of symptom onset, levels of the protein S100B were higher and levels of sRAGE were lower in hemorrhagic strokes compared to ischemic strokes. A combination of these markers showed reasonable ability to distinguish the two types early on.11PubMed. Differentiating ischemic from hemorrhagic stroke using plasma biomarkers: the S100B/RAGE pathway These markers are not yet accurate enough to replace emergency brain imaging, but they could prove useful in settings where a CT scanner is not immediately available.
In brain cancer, the concept of “liquid biopsy” applies to glioblastoma, the most aggressive primary brain tumor. Circulating tumor DNA shed by the tumor into the bloodstream has shown potential for monitoring treatment response and detecting recurrence. However, the blood-brain barrier limits how much tumor DNA reaches the circulation, and clinical validation is still underway.12PubMed Central. Liquid biopsy and glioblastoma
Autoimmune encephalitis, a group of conditions where the immune system attacks the brain and causes confusion, memory loss, or seizures, can also be confirmed through blood work. Detection of specific autoantibodies in serum serves as a confirmatory diagnosis for these syndromes.13PubMed Central. The Laboratory Diagnosis of Autoimmune Encephalitis Unlike many of the newer biomarkers discussed here, autoantibody testing for these conditions is already well established in clinical neurology.
Tiny Packages From the Brain
One of the more intriguing developments involves extracellular vesicles, sometimes called exosomes, that originate in the brain. These are nanoscale membrane-enclosed parcels that neurons and other brain cells release, carrying proteins, RNA fragments, and other molecular cargo. Some of these vesicles cross the blood-brain barrier and can be isolated from a standard blood draw, effectively serving as a “liquid biopsy” of the brain’s biochemical state.14PubMed Central. CNS-Derived Blood Exosomes as a Promising Source of Biomarkers: Opportunities and Challenges
Researchers have developed methods to enrich neuron-derived extracellular vesicles from blood and examine their contents for disease-specific signatures. In Alzheimer’s disease and related disorders, the molecular contents of these vesicles reflect changes occurring during neurodegeneration, including alterations in insulin signaling within the brain.15PubMed Central. Neuron-derived extracellular vesicles as a liquid biopsy for brain insulin dysregulation in Alzheimer’s disease and related disorders The approach is still largely in the research phase, but it represents a fundamentally different strategy from measuring free-floating proteins: instead of catching whatever leaks through the barrier, you are intercepting intentional biological mail.
What About Mental Health Conditions?
Depression, schizophrenia, and other psychiatric disorders lack the kind of definitive blood biomarkers that are emerging for neurodegenerative diseases. There is no blood test that diagnoses major depression the way p-tau217 can flag Alzheimer’s pathology. However, research has identified promising candidate markers in blood, spanning inflammatory signals, neurotrophic factors, and metabolic and neuroendocrine markers.16PubMed Central. Biomarkers for depression: recent insights, current challenges and future prospects
Where blood markers may matter most for psychiatry is in predicting treatment response. Elevated levels of inflammatory markers in blood have been associated with resistance to conventional antidepressants and worse outcomes. Identifying patients with inflammatory abnormalities early could help clinicians select more appropriate treatments from the start rather than cycling through medications that are unlikely to work.17Medical Research Archives. The Role of Neuroinflammation and Inflammatory Biomarkers in Major Depressive Disorder The goal is not to replace clinical evaluation for a diagnosis of depression but to add a biological layer that helps personalize treatment.
What Can Throw Off the Results
Blood-based brain biomarkers do not exist in a vacuum. Several non-neurological factors can raise or lower the numbers in ways that mimic or mask brain disease. For NfL in particular, age is by far the most powerful influence, especially in people over 60.18PubMed Central. Factors influencing serum neurofilament light chain levels in normal aging Kidney function also matters substantially. In a large study of elderly patients, a model combining just age and kidney function explained about 45 percent of the variation in blood NfL levels, meaning nearly half of what the test measures in older adults has nothing to do with the brain.19PubMed Central. Renal Function and Body Mass Index Contribute to Serum Neurofilament Light Chain Levels in Elderly Patients With Atrial Fibrillation Body mass index had an independent inverse relationship as well, with heavier individuals tending to show lower NfL levels. For clinicians interpreting results, this means an elevated NfL in an older person with reduced kidney function is much less informative than the same reading in a younger person with healthy kidneys.
Even sleep can shift biomarker levels. In a controlled study of young men, a single night of sleep deprivation increased the evening-to-morning ratio of total tau in plasma by about 17 percent, while amyloid-beta 42 and GFAP showed significant decreases over the day across conditions.20PubMed Central. Effects of acute sleep loss on diurnal plasma dynamics of CNS health biomarkers in young men These fluctuations reinforce the importance of standardizing when and under what conditions blood is drawn for these tests.
Sample Handling Matters More Than You Might Think
The fragility of some of these biomarkers creates a practical challenge for labs. Amyloid-beta proteins in blood begin to degrade quickly after a sample is drawn. One study found that amyloid-beta 40 and 42 levels in both serum and plasma were significantly lower when blood processing was delayed by 24 hours or more, and repeated freeze-thaw cycles further degraded the signal.21PubMed Central. Pre-Analytical Variables Influencing Stability of Blood-Based Biomarkers of Neuropathology Separate research confirmed that amyloid concentrations start declining within an hour of the blood draw if the sample is not centrifuged promptly, with losses reaching around 10 percent by six hours.22Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring. Preanalytical sample handling recommendations for Alzheimer’s disease plasma biomarkers The type of collection tube and anticoagulant used also influenced results, particularly for tau measurements.
These details matter because a blood test is only as good as the sample feeding it. Clinics adopting these tests will need standardized protocols for collection, processing time, storage, and shipping. Without them, results from one lab might not mean the same thing as results from another, which would undermine the whole point of having a simple, accessible test.
Cost and the Access Problem
One of the most compelling arguments for blood-based brain testing is economic. Confirming Alzheimer’s pathology currently requires either a PET brain scan or a lumbar puncture, both of which are expensive, scarce, and uncomfortable. A cost-effectiveness analysis found that using blood biomarkers to triage patients before PET scanning identified over 98 percent of PET-positive patients at a lower average cost per diagnosis than PET alone. When PET access was limited to half of the patient population, blood testing identified about 91 percent more positive patients at a fraction of the cost per diagnosis.23PubMed Central. Cost-effectiveness analysis of blood-based biomarker testing in the diagnosis of Alzheimer’s disease pathology Blood biomarkers are also significantly less invasive than spinal taps, which matters a great deal for patient willingness to get tested in the first place.
That said, blood tests are generally less accurate on their own than PET or cerebrospinal fluid analysis, and some researchers emphasize the need for multiple biomarkers together to achieve sufficient precision.24PubMed. Cost-effectiveness comparison between blood biomarkers and conventional tests in Alzheimer’s disease diagnosis The likely clinical model is not “blood test instead of everything else” but “blood test first, then imaging if needed,” which could dramatically reduce the number of expensive scans performed while catching most cases.
Ethical Questions Around Early Detection
Being able to detect Alzheimer’s pathology in someone’s blood before they have any symptoms raises questions that the medical community is still working through. While the physical risk of a blood draw is minimal, the psychological and social consequences of learning you have early-stage brain disease can be significant. Potential harms include emotional distress, discrimination, stigma, and financial consequences, particularly for people who are still working.25npj Dementia. An ethical framework for the clinical use of Alzheimer’s disease biomarker testing A positive result from a blood test does not guarantee someone will develop dementia, and for many people, the uncertainty of a probabilistic result may be harder to cope with than no information at all.
Broader ethical concerns include ensuring equitable access across different populations and clinical settings, managing how results are communicated to patients and families, and deciding when testing has enough clinical utility (such as the availability of disease-modifying treatments) to justify routine use.26Alzheimer’s & Dementia. Lessons Learned: Social and Ethical Issues Related to Clinical Implementation of Blood‐Based Biomarkers for Alzheimer’s Disease The arrival of new anti-amyloid drugs has intensified these discussions, because identifying amyloid-positive patients through blood testing is a prerequisite for prescribing these treatments, giving blood biomarkers an immediate clinical purpose beyond prediction.
Machine Learning and Multi-Marker Panels
The future of blood-based brain diagnostics likely involves combining many markers at once and using algorithms to interpret them. In the Framingham Heart Study, machine learning models trained on a panel of 38 blood biomarkers predicted incident dementia with moderate accuracy. When the models were refined to the nine most informative markers, accuracy improved, reaching an area under the curve of about 0.76.27PubMed Central. Identifying Blood Biomarkers for Dementia Using Machine Learning Methods in the Framingham Heart Study That is not high enough for a standalone diagnostic test, but it suggests blood biomarkers carry meaningful prognostic information even in people who have no symptoms yet.
Other researchers are using machine learning to identify spectral signatures of known Alzheimer’s proteins in blood plasma, essentially using infrared spectroscopy combined with algorithms to detect molecular fingerprints that correspond to amyloid-beta, phosphorylated tau, and GFAP.28eClinicalMedicine. Development and validation of machine learning models with blood-based digital biomarkers for Alzheimer’s disease diagnosis: a multicohort diagnostic study Research on multi-pathway biomarker panels has also revealed that different blood markers change in a stereotyped sequence as Alzheimer’s progresses: amyloid markers shift first, followed by markers of astrocyte activation, then tau, then nerve fiber damage, and finally vascular markers.29Alzheimer’s & Dementia. A Multi‐Pathway Blood‐Based Biomarker Panel Reveals Stereotyped Progression of Blood Biomarker Changes in Alzheimer’s Disease Knowing which markers change first could eventually allow clinicians to stage the disease from a single blood draw, telling patients not just whether Alzheimer’s pathology is present but roughly how far along it is.
Pediatric Brain Injury
Children present their own diagnostic challenges. Young children often cannot articulate symptoms clearly, and repeated imaging carries radiation concerns. Blood biomarkers for pediatric traumatic brain injury are an active area of research, with studies exploring whether the same proteins used in adults, including NfL, GFAP, and S100B, can help diagnose and predict outcomes in children who have experienced moderate to severe head injuries. Early evidence suggests these markers could allow earlier and more accurate assessment than relying on clinical observation and imaging alone, though pediatric reference ranges and confounders differ from adult values and require their own validation work.